Author

Jiajin Ma

Observed name: J. Ma

Institution: Soochow University

Observed institutions: Soochow University, Xijing Hospital

ORCID: 0009-0001-1742-4964

Observed ORCID: 0009-0001-1742-4964

OpenAlex ID: A5013099909

CX3CR1 + CD8 + T cells: Key players in antitumor immunity

2024 · Jiajin Ma, Yue Wu, et al. · Cancer Science · 13

CD8+ TEMRA cells: A double-edged sword in immunity and disease—Mechanisms and therapeutic targets

2026 · Jiajin Ma, Yue Wu, et al. · International Immunopharmacology · 3

Tumor-infiltrating CD103+CD8+hnRNPA2B1+ tissue-resident T cells indicate poor prognosis in patients with clear cell renal cell carcinoma

2025 · Yingting Liu, Jiajin Ma, et al. · Journal of Leukocyte Biology · 1

CX3CR1 identifies a potent effector CD8+ T cell subset associated with anti-PD-1 therapeutic efficacy in colorectal cancer

2026 · Jiajin Ma, Yue Wu, et al. · Frontiers in Immunology

AIM2 in Regulatory T Cells Restrains Anti–PD-1 Immunotherapy Efficacy by Reinforcing Immune Suppression in Colorectal Cancer

2025 · Nuo Wang, Hongwei Jiang, et al. · SSRN Electronic Journal

1217 Itaconate inhibits dendritic cell and CD8+T cell-mediated autoimmune response and halts vitiligo depigmentation

2023 · Y. Wang, J. Ma, et al. · Journal of Investigative Dermatology

Pb2080: Efficacy and Safety of Bendamustine-based Regimens as First-line Treatment for Indolent B-cell Non-hodgkin Lymphoma: a Prospective, Multicenter, Real-world Study in China

2022 · S. Li, S.-J. Wen, et al. · HemaSphere

Works count: 7

Citation count: 17

H-index: 2

I10-index: 1